Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Mindset Pharma identifies additional drug candidates from 'Family 3' psilocybin compounds

Mindset Pharma identifies additional drug candidates from 'Family 3' psilocybin compounds

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo joined Proactive to discuss the significance of synthesizing additional promising candidates from its Family 3 of next-generation drug candidates.

The duo say the group will initiate proof of concept preclinical studies to further measure the viability of these compounds as daily pro-cognitive take-home medication.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK